# BPC-157: Broad Rodent Support, a Thin Human Record > BPC-157: Research Overview — British Colombia Peptides — A cited literature summary of BPC-157: mechanism, angiogenesis and tissue-repair findings, community-reported effects labeled anecdotal, and the safety cautions the current evidence base supports. **01 / RESEARCH PEPTIDE FUNDAMENTALS** The gastric pentadecapeptide most associated with tissue repair — angiogenesis, tendon healing and gastric protection in animal models, and three small human pilots. **BPC-157 code reference** BPC-157: 20% for a first order, 15% for any order - `GRANT` — 20% off your first order (New customers only. First order.) - `GRANT15` — 15% off any order (No minimum. Applies to repeat orders.) ![Oath Research BPC-157, sold as research material at oathresearch.com](https://oathresearch.com/wp-content/uploads/2025/08/B157-3-768x768.png) *Both codes are current. Applying either one makes no payment to this site.* ## The short version BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice. In rodent studies it has repeatedly accelerated healing of damaged tissue — stomach ulcers, torn tendons, and injured blood vessels — and the leading explanation is that it promotes *angiogenesis*, the growth of new blood vessels, through a receptor called VEGFR2. The catch: almost all of that evidence is from rats, dogs and cell cultures. As of a 2025 review, only three small human pilot studies exist, and no large controlled human trial has been run [2]. One of those pilots, an intravenous safety study in two adults, found it well tolerated with no measured harm — but a study of two people proves tolerability, not benefit [1]. BPC-157 is not an approved drug anywhere; it is sold as a research chemical, and this page treats it as investigational, exactly as the current literature does. ## What it is BPC-157 (Body Protection Compound 157, also called pentadecapeptide BPC 157 or PL 14736) is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22. It is derived from a partial sequence of a human gastric-juice protein and was engineered to be more stable than the parent protein fragment, which is why researchers have been able to study it across dozens of animal models spanning gut, tendon, muscle, nerve and vascular tissue. ## How it works The best-characterized mechanism is angiogenic: BPC-157 up-regulates the VEGFR2 receptor and promotes its internalization, activating the downstream VEGFR2-Akt-eNOS (nitric-oxide) signaling pathway [4]. In practical terms, this means more new blood vessels reaching damaged tissue, which speeds delivery of oxygen and repair signals. Additional proposed routes include the FAK-paxillin complex, which governs cell migration into a wound; growth-hormone-receptor sensitization in tendon fibroblasts, tying it to connective-tissue repair specifically [6]; and modulation of the nitric-oxide system and serotonergic/dopaminergic neurotransmission along what researchers call the brain-gut axis [7]. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes) and modest bioavailability, with rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [3] — a molecule that acts fast and clears fast, at least in animals. ## What the research shows The foundational work is decades of rodent studies. In Wistar rats, BPC 157 reduced gastric ulcer area by 45.7-65.6% at higher doses and accelerated the rebuilding of the stomach lining, with intramuscular delivery outperforming intragastric [5]. In a fully transected rat Achilles tendon model, it improved biomechanical strength, functional recovery and collagen organization compared with untreated controls, and separately stimulated tendon-cell outgrowth in a dish [6]. In chick and rat vascular models plus human endothelial cells, it increased vessel density and sped blood-flow recovery after induced ischemia, an effect that disappeared when researchers blocked the cell's endocytosis machinery — direct evidence for the VEGFR2 mechanism [4]. A review of brain-gut-axis studies positions it as a modulator of serotonin and dopamine signaling and several intracellular repair pathways [7]. On the human side, the record is far thinner. A 2025 pilot gave two healthy adults intravenous BPC-157 up to 20 mg; both tolerated it with no adverse events and no measurable change in cardiac, liver, kidney, thyroid or glucose markers [1]. A 2025 narrative review surveying the whole field states plainly that "only three pilot studies have examined BPC-157 in humans," that rigorous large-scale trials are lacking, and that BPC-157 should be treated as investigational given regulatory controversy and unregulated availability [2]. ## Reported effects, cautions & safety *Reported effects (anecdotal, not clinical evidence):* the effect people in research-use communities describe most often is faster-feeling recovery from tendon, ligament and joint injuries — old sprains, tennis elbow, rotator-cuff strain — sometimes within one to three weeks. Others describe less joint stiffness, improved digestive comfort, and occasionally faster skin healing, all of which they connect to BPC-157's reported tissue-repair and blood-vessel effects. These are personal accounts from forums and clinic write-ups, not results from a controlled trial, and the published human evidence behind them is very thin. On the adverse side, the most common report by far is a local injection-site reaction — brief stinging, redness or a small bump that people say fades within a day. Mild nausea or stomach upset, first-week fatigue, headache, and occasional dizziness or flushing round out the more common reports; heart palpitations are rarely mentioned and, when they are, commentators treat a persistent racing heartbeat as a reason to stop and seek medical evaluation. *Cited cautions from the literature:* - **The human evidence is extremely thin** — almost everything known comes from rodents, and 2025 reviews put the entire human pilot record at three small studies. Animal results should never be read as proven human benefit. - **Much of the foundational research comes from one research group**, limiting independent replication of the broader findings [2]. - **Not an approved drug**; sold through non-regulated channels where identity, purity and content are unverified outside formal studies [2]. - **Strong pro-angiogenic activity is a theoretical cancer concern** — because tumors also depend on new blood-vessel growth, a strongly pro-angiogenic agent is mechanistically flagged as a caution for anyone with an active or suspected malignancy. - **Possible interaction with serotonin-affecting medicines**, based on rodent work showing BPC-157 alters serotonergic activity — theoretical, not confirmed in a human interaction study. - **Banned in competitive sport** by the World Anti-Doping Agency under its non-approved-substances category. - **Unstudied in pregnancy, breastfeeding and children** — no human safety data exist for these groups. ## Where it fits in Research Peptide Fundamentals BPC-157 leads this desk because it is the compound with the widest gap between animal-model enthusiasm and human evidence — a pattern worth understanding before reading the other four. [Semaglutide](/semaglutide) sits at the opposite end of that spectrum, with a deep, approved human trial record. [Ipamorelin](/ipamorelin) shares BPC-157's thin human data problem but for a different reason: its one human trial actually ran, and missed its endpoint. See the [comparison page](/compare) for how all five stack up on evidence maturity. --- A literature desk on five research peptides, read against the Canadian regulatory backdrop — not a clinic, not a vendor, not a prescription.